COVID-19: A thrombotic disease?

Cédric Hermans, Catherine Lambert Published in the journal : May 2020 Category : Hémostase

Summary :

COVID-19, especially in its severe form, is associated with a coagulopathy responsible for an increased incidence of venous and arterial thrombosis, pulmonary embolism, and pulmonary microthrombosis. Biologically, it results in increased D-dimer levels, which is of diagnostic and prognostic relevance. Depending on its severity, the COVID-19 infection requires a treatment with low-molecular-weight heparin (LMWH) at preventive or semi-therapeutic doses. In case of proven or strongly suspected thrombosis, anticoagulation with LMWH at therapeutic doses is recommended.

Key Words

COVID-19, thrombosis, coagulopathy, D-dimers, anticoagulation